Relmada Therapeutics Inc

Relmada Therapeutics Inc(RLMD)のニュースとイベント

$4.460

+0.102 (+2.29%)終値時点

RLMD のニュース

RLMD のイベント

8/6 18:00

Relmada Cash Reserves Reach $217.7M, Expected to Fund Operations Through 2029

As of June 30, 2026, the company's cash, cash equivalents, and short-term investments balance was $217.7M, which is expected to provide sufficient resources to fund operations through 2029. "Relmada has entered a critical execution phase as we prepare NDV-01 for registrational development. With FDA alignment, a robust clinical dataset, an experienced leadership team, and capital expected to fund operations through completion of the Phase 3 RESCUE program, we believe the Company is well positioned to create significant long-term value," said CEO Sergio Traversa.

7/28 09:30

Relmada Therapeutics Appoints Bipin Dalmia as Chief Business Officer

Relmada Therapeutics announced the appointment of Bipin Dalmia as chief business officer. Bipin will lead Relmada's corporate strategy, commercial planning, and business development activities, reporting directly to CEO Sergio Traversa.

7/28 09:30

Relmada Therapeutics Appoints Bipin Dalmia as Chief Business Officer

Relmada Therapeutics announced the appointment of Bipin Dalmia as chief business officer. Dalmia will lead Relmada's corporate strategy, commercial planning, and business development activities, reporting directly to CEO Sergio Traversa. Dalmia most recently served as senior VP, global head of portfolio strategy and business development at Ferring Pharmaceuticals, where he led the company's uro-oncology franchise, including the U.S. launch and global lifecycle and manufacturing strategy for Adstiladrin, the first FDA-approved intravesical gene therapy for BCG-unresponsive non-muscle invasive bladder cancer patients

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める